Case report demonstrates leukocytoclastic vasculitis with purpura in a metastatic colorectal cancer patient receiving panitumumab, highlighting a rare cutaneous adverse reaction.
Key Points
To report a rare case of panitumumab-induced leukocytoclastic vasculitis presenting with purpuric lesions in a patient undergoing treatment for metastatic colorectal cancer.
Evaluated a 51-year-old male with KRAS wild-type metastatic colorectal cancer who presented with lower-extremity palpable purpura and petechiae 10 days after five cycles of FOLFOX plus panitumumab.
Performed a punch skin biopsy of the purpuric lesions to establish a definitive histopathological diagnosis.
Withdrew panitumumab during cycle six and administered oral corticosteroids alongside topical treatment.
Skin biopsy confirmed a definitive diagnosis of leukocytoclastic vasculitis.
Discontinuation of panitumumab combined with corticosteroid therapy led to complete regression and resolution of the purpuric lesions, permitting continuation of mFOLFOX-6.